Affiliation:
1. Normandie University, Unicaen, Centre d’Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000 Caen, France
Abstract
The multifactorial nature of some diseases, particularly neurodegenerative diseases such as Alzheimer’s disease, frequently requires the use of several drugs. These drug cocktails are not without drawbacks in terms of increased adverse effects, drug–drug interactions or low adherence to treatment. The use of pleiotropic drugs, which combine, within a single molecule, several activities directed against distinct therapeutic targets, makes it possible to overcome some of these problems. In addition, these pleiotropic drugs generally lead to the expression of a synergy of effects, sometimes greater than that observed with a combination of drugs. This article will review, through recent examples, the different kinds of pleiotropic drugs being studied or already present on the market of medicines, with a focus on the structural aspect of such drug design.
Reference52 articles.
1. Pergamon Press Ltd. (1960). Experimental Researches on Specific Therapy, Himmelweit. The collected papers of Paul Ehrlich.
2. Handler, N., and Bushmann, H. (2017). Drug Selectivity: An Evolving Concept in Medicinal Chemistry, Wiley-VCH Verlag GmbH & Co.
3. Multi-Target Directed Ligands to combat neurodegenerative diseases;Cavalli;J. Med. Chem.,2008
4. Parvin, N., and Jozwiak, K. (2022). Effects of linkers and substitutions on Multi-Target Directed Ligands for Alzheimer’s diseases: Emerging paradigms and strategies. Int. J. Mol. Sci., 23.
5. Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?;Tumiatti;J. Med. Chem.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献